iShares Biotechnology ETF
IBB
IBB
955 hedge funds and large institutions have $6.37B invested in iShares Biotechnology ETF in 2021 Q4 according to their latest regulatory filings, with 184 funds opening new positions, 304 increasing their positions, 248 reducing their positions, and 66 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
955
Holders Change
+105
Holders Change %
+12.35%
% of All Funds
14.75%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.15%
New
184
Increased
304
Reduced
248
Closed
66
Calls
$453M
Puts
$409M
Net Calls
+$43.6M
Net Calls Change
+$34.3M
Top Buyers
| 1 |
Citigroup
New York
|
$244M |
| 2 |
Morgan Stanley
New York
|
$580M |
| 3 |
E
Ergoteles
New York
|
$33.7M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
$200M |
| 5 |
DC
DeDora Capital
Napa,
California
|
$24.8M |
Top Sellers
| 1 |
Barclays
London,
United Kingdom
|
$48.2M |
| 2 |
JPMorgan Chase & Co
New York
|
$73.9M |
| 3 |
Goldman Sachs
New York
|
$179M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
$196M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
$1.05M |
